PortfoliosLab logoPortfoliosLab logo
CRON vs. SGMO
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CRON vs. SGMO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cronos Group Inc. (CRON) and Sangamo Therapeutics, Inc. (SGMO). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CRON vs. SGMO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CRON
Cronos Group Inc.
-4.56%30.20%-3.35%-17.72%-35.20%-43.52%-9.52%-26.18%34.43%600.87%
SGMO
Sangamo Therapeutics, Inc.
-38.07%-58.82%87.74%-82.70%-58.13%-51.94%86.44%-27.09%-30.00%437.70%

Fundamentals

EPS

CRON:

-$0.04

SGMO:

-$0.41

PS Ratio

CRON:

3.33

SGMO:

1.97

Total Revenue (TTM)

CRON:

$193.36M

SGMO:

$39.55M

Gross Profit (TTM)

CRON:

$62.76M

SGMO:

$25.32M

EBITDA (TTM)

CRON:

$16.20M

SGMO:

-$117.16M

Returns By Period

In the year-to-date period, CRON achieves a -4.56% return, which is significantly higher than SGMO's -38.07% return.


CRON

1D
0.00%
1M
-4.56%
YTD
-4.56%
6M
-5.64%
1Y
40.22%
3Y*
8.97%
5Y*
-23.23%
10Y*

SGMO

1D
5.35%
1M
-39.50%
YTD
-38.07%
6M
-61.44%
1Y
-54.38%
3Y*
-47.13%
5Y*
-53.74%
10Y*
-27.19%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRON vs. SGMO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CRON
CRON Risk / Return Rank: 6868
Overall Rank
CRON Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
CRON Sortino Ratio Rank: 7070
Sortino Ratio Rank
CRON Omega Ratio Rank: 6565
Omega Ratio Rank
CRON Calmar Ratio Rank: 6969
Calmar Ratio Rank
CRON Martin Ratio Rank: 6666
Martin Ratio Rank

SGMO
SGMO Risk / Return Rank: 1616
Overall Rank
SGMO Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
SGMO Sortino Ratio Rank: 2323
Sortino Ratio Rank
SGMO Omega Ratio Rank: 2323
Omega Ratio Rank
SGMO Calmar Ratio Rank: 99
Calmar Ratio Rank
SGMO Martin Ratio Rank: 88
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CRON vs. SGMO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cronos Group Inc. (CRON) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CRONSGMODifference

Sharpe ratio

Return per unit of total volatility

0.87

-0.51

+1.38

Sortino ratio

Return per unit of downside risk

1.67

-0.26

+1.92

Omega ratio

Gain probability vs. loss probability

1.19

0.97

+0.22

Calmar ratio

Return relative to maximum drawdown

1.44

-0.87

+2.30

Martin ratio

Return relative to average drawdown

2.88

-1.54

+4.42

CRON vs. SGMO - Sharpe Ratio Comparison

The current CRON Sharpe Ratio is 0.87, which is higher than the SGMO Sharpe Ratio of -0.51. The chart below compares the historical Sharpe Ratios of CRON and SGMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


CRONSGMODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.87

-0.51

+1.38

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.43

-0.51

+0.08

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.29

Sharpe Ratio (All Time)

Calculated using the full available price history

0.43

-0.16

+0.59

Correlation

The correlation between CRON and SGMO is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

CRON vs. SGMO - Dividend Comparison

Neither CRON nor SGMO has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CRON vs. SGMO - Drawdown Comparison

The maximum CRON drawdown since its inception was -93.16%, smaller than the maximum SGMO drawdown of -99.50%. Use the drawdown chart below to compare losses from any high point for CRON and SGMO.


Loading graphics...

Drawdown Indicators


CRONSGMODifference

Max Drawdown

Largest peak-to-trough decline

-93.16%

-99.50%

+6.34%

Max Drawdown (1Y)

Largest decline over 1 year

-26.91%

-69.70%

+42.79%

Max Drawdown (5Y)

Largest decline over 5 years

-82.78%

-98.05%

+15.27%

Max Drawdown (10Y)

Largest decline over 10 years

-99.06%

Current Drawdown

Current decline from peak

-89.41%

-99.48%

+10.07%

Average Drawdown

Average peak-to-trough decline

-63.12%

-83.93%

+20.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.42%

39.13%

-25.71%

Volatility

CRON vs. SGMO - Volatility Comparison

The current volatility for Cronos Group Inc. (CRON) is 10.86%, while Sangamo Therapeutics, Inc. (SGMO) has a volatility of 28.34%. This indicates that CRON experiences smaller price fluctuations and is considered to be less risky than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


CRONSGMODifference

Volatility (1M)

Calculated over the trailing 1-month period

10.86%

28.34%

-17.48%

Volatility (6M)

Calculated over the trailing 6-month period

30.52%

78.81%

-48.29%

Volatility (1Y)

Calculated over the trailing 1-year period

46.44%

108.44%

-62.00%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

54.68%

106.51%

-51.83%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

75.20%

95.01%

-19.81%

Financials

CRON vs. SGMO - Financials Comparison

This section allows you to compare key financial metrics between Cronos Group Inc. and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
91.31M
14.23M
(CRON) Total Revenue
(SGMO) Total Revenue
Values in USD except per share items